- Disease
- Tuesday, 23 Jun 2020
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
"AGEN1181 is an Fc-engineered anti-CTLA-4 that has shown exciting clinical activity in an early phase 1 clinical trial, which was recently presented at ASCO," said Dr. Antoine Tanne, Lead Scientist, Agenus Immune Biology Team. "Today, at AACR, we report that combinations with AGEN1181 demonstrate curative responses in preclinical models resistant to anti-PD-1. These data illustrate the potential of combining allogeneic cell therapies with checkpoint antibodies, such as AGEN1181, to deliver curative benefit in difficult to treat settings."
Related Industry Updates
Death Toll in China Rose to Nine From a new flu Coronavirus
Jan 22, 2020
Stock Futures slips as coronavirus cases outside China rise
Feb 20, 2020
Kaiser Permanente Extends COVID-19 Cost Waiver Through Dec. 31, 2020
May 29, 2020
Tumor Ablation Market 2021 Strong Revenue, Competitive Outlook by Top Competitors And Forecast To 2027
Apr 27, 2021
Industries That will Withstand the COVID-19 Storm
Mar 30, 2020
Australia confirms end to longest boom as fires, pandemic destroy growth
Jun 03, 2020
Global stocks pause as investors turned cautious after a 42% surge since March
Jun 08, 2020
Follow us on
